Paul Shin

Paul Shin

Auto-generated profile, based on publicly available information

Paul Shin

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. 1

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
YSYi Song
Yi Song
TBThomas Boerner
Thomas Boerner
EDEsther Drill
Esther Drill
PSPaul Shin
Paul Shin
SKSandeep Kumar
Sandeep Kumar
WJWilliam R. R Jarnagin
William R. R Jarnagin
Purpose: Intrahepatic cholangiocarcinoma (IHC) is a heterogeneous tumor. The hidden-genome classifier, a supervised machine learning–based algorithm, was used to quantify tumor heterogeneity and improve classification. Experimental Design: A retrospective review of 1,370 patients with IHC, extrahepatic cholangiocarcinoma (EHC), gallbladder cancer (GBC), hepatocellular carcinoma (HCC), or biphenotypic tumors was conducted. A hidden-genome model classified 527 IHC based on genetic similarity to EHC/GBC or HCC. Genetic, histologic, and clinical data were correlated. Results: In this study, 410 IHC (78%) had >50% genetic homology with EHC/GBC; 122 (23%) had >90% homology (“biliary class”), characterized by alterations of KRAS, SMAD4, and CDKN2A loss; 117 IHC (22%) had >50% genetic homology with HCC; and 30 (5.7%) had >90% homology (“HCC class”), characterized by TERT alterations. Patients with biliary- versus non-biliary-class IHC had median overall survival (OS) of 1 year (95% CI, 0.77, 1.5) versus 1.8 years (95% CI, 1.6, 2.0) for unresectable disease and 2.4 years (95% CI, 2.1, NR) versus 5.1 years (95% CI, 4.8, 6.9) for resectable disease. Large-duct IHC (n = 28) was more common in the biliary class (n = 27); the HCC class was composed mostly of small-duct IHC (64%, P = 0.02). The hidden genomic classifier predicted OS independent of FGFR2 and IDH1 alterations. By contrast, the histology subtype did not predict OS. Conclusions: IHC genetics form a spectrum with worse OS for tumors genetically aligned with EHC/GBC. The classifier proved superior to histologic subtypes for predicting OS independent of FGFR2 and IDH1 alterations. These results may explain the differential treatment responses seen in IHC and may direct therapy by helping stratify patients in future clinical trials.

15 August 2024
Verified
Other
Open access
YSYi Song
Yi Song
TBThomas Boerner
Thomas Boerner
EDEsther Drill
Esther Drill
PSPaul Shin
Paul Shin
SKSandeep Kumar
Sandeep Kumar
WJWilliam R. R Jarnagin
William R. R Jarnagin
This table reports the lasso-selected active genetic predictors of the hidden-genome model. The predictive power is represented by the GBC/EHC odds ratio (OR) or HCC OR. The max OR is the greater of the two values. The Shannon-Jensen importance is represented by the average individual effect and the max individual effect. FGFR2 fusion and BAP1 mutation were not identified by the algorithm as lasso-selected active genetic predictors and had very low Shannon-Jensen importance. Therefore, FGFR2 fusion and BAP1 mutation were not included in the table.

15 August 2024
Verified
Other
Open access
YSYi Song
Yi Song
TBThomas Boerner
Thomas Boerner
EDEsther Drill
Esther Drill
PSPaul Shin
Paul Shin
SKSandeep Kumar
Sandeep Kumar
WJWilliam R. R Jarnagin
William R. R Jarnagin
Supplementary Figure S3 Overall survival stratified by biliary class in non-resected patients (A) and resected patients (B) without IDH1 mutations or FGFR2 fusion. Interaction between the presence of any IDH1 or FGFR2 mutation and the genomic classification was insignificant in both non-resected (p = 0.6) and resected patients (p = 0.5). See the main text for median survival estimates in each case.


15 August 2024
Verified
Other
Open access
YSYi Song
Yi Song
TBThomas Boerner
Thomas Boerner
EDEsther Drill
Esther Drill
PSPaul Shin
Paul Shin
SKSandeep Kumar
Sandeep Kumar
WJWilliam R. R Jarnagin
William R. R Jarnagin
Supplementary Figure S2 The genomic alterations in extrahepatic biliary tumors and hepatocellular carcinoma are visualized using two-dimensional embeddings of the lasso-selected active genetic predictors in the training data, which includes 190 extrahepatic cholangiocarcinoma (dark blue), 226 gallbladder cancer (light blue) and 277 hepatocellular carcinoma (orange). Each point in the plot represents the genetic profile of a single tumor. EHC: extrahepatic cholangiocarcinoma; GBC: gallbladder cancer; HCC: hepatocellular carcinoma.